替比夫定治疗HBeAg阳性慢性乙型肝炎和肝硬化患者血清免疫球蛋白和补体水平的变化

doi:10.3969/j.issn.1672-5069.2015.06.028

Abstract

Wang Fang， Yang Xingkong， Kou Junfeng， et al.. Serum immuneglobulin IgG, IgA, IgM and complement C3, C4 levels in patients with HBeAg positive chronic hepatitis B and liver cirrhosis after telbivudine treatment[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(6): 672-673.

References

[1] Webster GJ,Reignat S,Maini MK,etal. Incubation phase of acute hepatitis B in man:dynamic of cellular immune mechanisms. Hepatology,2000,32（5）:1117-1124.
[2] Rapicetta M,Ferrari C,LevreroM. Viral determinants and host immune responses in the pathogenesis of HBV infection. J Med Virol,2002,67（3）:454-457.
[3] TannerMS. Mechanisms of liver injury relevant to pediatric hepatology. Crit Rev Clin Lab Sci,2002,39（1）:51-61.
[4] Maini MK,Boni C,Lee CK,et al. The role of virus specific CD8 （+） cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med,2000,191（8）:1269-1280.
[5] Liaw YF,Gane E,Leung N,et al. 2 year GLOBE trial results: telbivudine is superior to lamivudine in patiants with chronic hepatitis B. Gstroenterology,2009,136（2）:486-495.
[6] Hou JL,Yin YK,Xu D,et al. A Phase Ⅲ comparative trial of telbivudine and lamivudine for treatment of chronic hepatitis B in Chinense patients:first year results. Presented at Shanghai-Hong kong international liver congress. March 25-28,2006,Poster 180.
[7] Evans A,Riva A,Cooksley H,etal. Program death expression during antiviral treatmentof chronic hepatitisB:Impact of hepatitis Be-antigen seroconversion. Hepatology,2008,48 （3）:759-769.
[8] 张梦军,周吉军,傅晓岚,等. 替比夫定对慢性乙型肝炎患者外周血细胞频率的影响及临床意义. 免疫学杂志,2010,26（7）：594-597.
[9] 朱斌,张平,王天宝,等. 替比夫定治疗慢性乙肝血清Th1 /Th2亚群细胞因子的水平变化. 临床肝胆病杂志,2009,25（6）：415-417.
[10] 韦丽霞,唐任光,杨柳,等. 免疫球蛋白及补体检测在肝炎诊断中的意义. 右江民族医学院学报,2006,28（2）：266-267.
[11] 陈斐,高国生. 乙型肝炎患者体液免疫指标的检测及临床意义.现代实用医学杂志,2011,23（8）：908-910.
[12] 赵良营,张娟. 病毒性肝炎血清免疫球蛋白和补体的研究.实用预防医学,2005,12（4）：860-861.
[13] 吴文娟,刘若英,杨春英,等. 血清乙肝病毒标记物与免疫球蛋白、补体水平的相关性研究. 贵州医药,2001,25（5）：413-414.
[14] 张雪华,李仲平. 血清补体C3、C4测定在病毒性肝炎患者中的临床意义. 临床辅助检查,2012,14（10）：258-259.
[15] 周新人,王方. 补体异常与肝硬化关系研究进展.实用肝脏病杂志,2014,17（6）：669-671.
[16] 王晗,王雪飞,王丽华,等. 不同肝病患者血清s CR1浓度变化及临床意义研究. 中国卫生检验杂志,2007,17（10）:1757-1758.
[17] 罗丽莎,张继万,周建丽,等. 慢性乙型肝炎患者红细胞天然免疫粘附功能与血清s CR1变化的相关性研究.检验医学与临床,2012,9（9）：1069-1071.
[18] 董格峰,刘典勇,王晶波,等. 重型肝炎患者血清可溶性补体受体Ⅰ型的变化及临床意义. 中华肝脏病杂志,2004,12（2）：108-109.
[19] Bugdaci MS,Alkim C,Karaca C,et al. Could complement C 4 be an alternative to biopsy forchronic hepatitis B histopathologic findings. J Clin Gastroenterol,2011,45（5）:449-455.

Serum immuneglobulin IgG, IgA, IgM and complement C3, C4 levels in patients with HBeAg positive chronic hepatitis B and liver cirrhosis after telbivudine treatment

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.